Experience with dupilumab in patients with atopic dermatitis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Atopic dermatitis (AD) is an immune-mediated skin disease with underlying Th2 cell activation and dysfunction of the epidermal barrier. Over the past decades, the prevalence of atopic diseases, including AD, bronchial asthma, allergic rhinitis and food allergy, has tended to increase in the global population. AD affects the quality of life of patients as a result of lack of sleep due to the frequent development of severe itching of the skin, concern of patients with the condition of the skin and their social stigmatization, more pronounced with a long and persistent course of the disease. Currently, AD remains an interdisciplinary problem; it is studied not only by dermatovenerologists, but also by allergists-immunologists and pediatricians, which is explained by the complex immunopathogenesis of the disease, the variety of its clinical manifestations, and sometimes difficulties arising in the choice of adequate therapy. Situations of a torpid course of the disease with the absence of desired effect of existing variety of treatment methods are not uncommon. Thus, the use of new methods of therapy, in particular, genetically engineered biological preparations, aimed at the main components of the pathogenesis of the disease, can be considered promising. This article provides basic information on AD, immunopathogenesis of AD, clinical cases of the use of the dupilumab, biological preparation of the interleukin-4 (IL-4)/IL-13 receptor inhibitor, in patients with severe forms of AD

全文:

受限制的访问

作者简介

Zareta Marshani

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation

Email: zbmarshani@mail.ru
Dermatovenerologist, Department of Dermatovenereology and Cosmetology Moscow, Russia

E. Svechnikova

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University

Moscow, Russia

参考

  1. Seegraber M., Srour J., Waiter A., Knop M., Wollenberg A. Dupilumab for treatment of atopic dermatitis, Exp Rev Clin Pharmacol. 2018. doi: 10.1080/17512433.2018.1449642.
  2. Wollenberg A., Oranje A., Deleuran M., et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729-47. doi: 10.1111/jdv.13599.
  3. Свечникова Е.В., Маршани З.Б., Ушакова Д.В., Ойноткинова О.Ш. Дупилумаб в практике врача: клинический случай пациента с тяжелой формой атопического дерматита. Клиническая дерматология и венерология. 2019;18(6):768-75.
  4. Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab 2015;66(Suppl 1):34-40. doi: 10.1159/000370226.
  5. Хегер П.Г Детская дерматология. Пер. с нем. Под ред. А.А. Кубановой, А.Н. Львова. М., 2013
  6. Максимова Ю.В., Свечникова Е.В., Максимов В.Н. и др. Полиморфизм некоторых генов иммунного ответа при атопическом дерматите. Клинническая дерматология и венерология. 2015;14(5):24-7
  7. Danso M.O., Van Drongelen V., Mulder A., et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941-50. doi: 10.1038/jid.2014.83.
  8. Brunner P.M., Guttman-Yassky E., Leung D.Y.M. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(Suppl. 4):S65-76. doi: 10.1016/j.jaci.2017.01.011.
  9. Gandhi N.A., Pirozzi G., Graham N.M.H. Commonality of the IL-4/IL-13 pathway in atopic diseases. Exp Rev Clin Immunol. 2017;13(5):42537. doi: 10.1080/1744666X.2017.1298443
  10. Максимова Ю.В., Свечникова Е.В., Максимов В.Н. и др. Клинический полиморфизм атопического дерматита и вульгарного ихтиоза при мутациях в гене филаггрина. Клиническая дерматология и венерология. 2015;14(5):157-65
  11. Leung D., Guttman-Yasky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-79. Doi: 10.1016/j. jaci.2014.08.008.
  12. Gooderham, et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3). Doi: 10.1016/j. jaad.2017.12.022.
  13. Ring J., Alomar A., Bieber T., et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-doi: 10.1111/j.1468-3083.2012.04635.x.
  14. Ring J., Alomar A., Bieber T., et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176-93. doi: 10.1111/j.1468-3083.2012.04636.x.
  15. Eichenfield L.F., Tom W.L., Berger T.G., et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32. doi: 10.1016/j.jaad.2014.03.023.
  16. Reitamo S., Wollenberg A., Schopf E., et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European tacrolimus ointment study group. Arch Dermatol. 2000;136(8):999-1006. doi: 10.1001/archderm.136.8.999.
  17. Heller M., Shin H.T., Orlow S.J., et al. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157(1):127-32. doi: 10.1111/j.1365-2133.2007.07947.x.
  18. Meggitt S.J., Reynolds N.J. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26(5):369-75. doi: 10.1046/j.1365-2230.2001.00837.x.
  19. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606-19. doi: 10.1111/j.1468-3083.2006.02023.x.
  20. Weatherhead S.C., Wahie S., Reynolds N.J., et al. An open-label, dose- ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346-51. doi: 10.1111/j.1365-2133.2006.07686.x.
  21. Sidbury R., Davis D.M., Cohen D.E., et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-49. Doi: 10.1016/j. jaad.2014.03.030.
  22. Press release (Regeneron Pharmaceuticals, Inc). Accessed July 05,2021 https://investor.regeneron. com/news-releases/news-release-details/regeneron-and-sanofi-announce-dupilumab-has-received-fda/
  23. Инструкция по медицинскому применению лекарственного препарата Дупиксент® РУ № ЛП-005440 от 04.04.19 с изменениями от 16.04.2021. [Instructions for the medical use of the drug Dupixent® RU No. LP-005440 dated 04/04/19 as amended on 04/16/2021.(In Russ.)].
  24. Summary of product characteristics (dupilumab). Accessed July 05, 2021. https://www.ema. europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf
  25. FDA: Highlights of Prescribing Information (Dupilumab). Accessed July 05, 2021. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf
  26. Simpson E.L., et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-48. Doi: 10.1056/ NEJMoa1610020.
  27. Giavina-Bianchi M.H., Giavina-Bianchi P., Rizzo L.V. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report. Einstein (Sao Paulo).2019;17(4):eRC4599. Doi: 10.31744/ einstein_journal/2019RC4599.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021